Overactive Bladder (OAB)
 
 

 

Ongoing Clinical Trials

Trial Status

CLOSED TO ENROLLMENT

Protocol Number:  UPC121908 STEP            01/2009 - Present
Sponsor:  Uroplasty
Title: 
Sustained therapeutic effects of Percutaneous Tibial Nerve Stimulation.

Purpose of Study
We are currently conducting an extension study of the Urgent PC system.  The purpose of this study is to observe and evaluate long-term therapy of Urgent PC for the treatment of overactive bladder (OAB) symptoms of urge incontinence, urinary urgency, and urinary frequency. 

For further information click here.




List of Completed Trials for Overactive Bladder (OAB)

Protocol Number:  C-2001-019                    12/2001 – 11/2002
Sponsor:  Alza Corporation
Title: 
A comparison study of the efficacy and tolerability of Ditropan® XL and Detrol® LA in the treatment of overactive bladder in women age 18 and older.

Protocol Number:  URO-101                    12/2005 – 09/2006
Sponsor:  Urigen Holdings Inc.
Title: 
A phase II multicenter, randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of intravesical alkalinized lidocaine-heparin for the symptoms of pelvic pain and urgency of bladder origin.

Protocol Number:  UPC032006                    09/2006 – 01/2009
Sponsor:  Uroplasty
Title: 
Overactive bladder innovative therapy trial—ORBIT Trial, a randomized study comparing Urgent PC percutaneous tibial nerve stimulation with standardized pharmacologic therapy (Detrol LA) in reducing the frequency of urinary voids.

Protocol Number:  A0221009                    12/2007 – 05/2009
Sponsor:  Pfizer, Inc.
Title: 
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fesoterodine as an “Add-On” Therapy in Men with Persistent Overactive Bladder Symptoms Under Monotherapy of Alpha Blocker for Lower Urinary Tract Symptoms.


Protocol Number:  UPC082008 SUmiT                10/2008 - 05/2009
Sponsor:  Uroplasty
Title: 
A prospective, multi-center, randomized, intention-to-treat, double blinded, sham-Controlled study.  Subjects are randomized 1:1 at enrollment to receive either Urgent PC or Sham intervention in treatment of Overactive Bladder symptoms. 


Clinical Research Coordinators:
Patricia Edwards, RN (336) 274-1114 ext. 5322
Karen Michael, RN (336) 274-1114 ext. 5328
E-mail address: research@allianceurology.com



Allscripts Alliance Urology Specialists. All Rights Reserved. Copyright © . Medfusion, Inc.
All trademarks and registered trademarks are of their respective companies.
Powered by Medfusion, Inc.
Medfusion
 
Alliance Urology Specialists. All Rights Reserved. Copyright © . Medfusion, Inc.
All trademarks and registered trademarks are of their respective companies.
Site powered by Medfusion, Inc.
Website Graphics by Vintage Marketing